annb0t
Top 20
Immutep Limited
Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC) Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 / anti-PD-L1 (âPD-Xâ) based 1st line therapy1 Key facts reported:
Median Overall Survival (OS) from therapy with efti in combination with pembrolizumab is 9.7 months 25% were progression free at 6 months and 36.5% were alive at 18 months2 Chemo-free therapy of efti in combin...
>>> Read more: Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC
Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC) Patients in this 2nd line setting had confirmed disease progression on anti-PD-1 / anti-PD-L1 (âPD-Xâ) based 1st line therapy1 Key facts reported:
Median Overall Survival (OS) from therapy with efti in combination with pembrolizumab is 9.7 months 25% were progression free at 6 months and 36.5% were alive at 18 months2 Chemo-free therapy of efti in combin...
>>> Read more: Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC
